FLT3 and acute myeloid leukemia: Collectively, although clinical outcomes in FLT3-ITD-mutated AML are complex and impacted by multiple factors, such as the patient’s baseline characteristics and co-occurring mutations, there is robust evidence that FLT3-ITD is an important prognostic biomarker, as recognized in international guidelines (e.g., NCCN and ELN).